GSK's oral gonorrhoea drug, gepotidacin, demonstrated non-inferiority to existing treatment in a late-stage trial.
GSK's oral gonorrhoea drug, gepotidacin, has met its primary goal of non-inferiority in a late-stage trial, compared to an existing combination treatment. The drug is being developed for use in adults and adolescents for the sexually transmitted infection, which affects about 82 million new people globally each year. If approved, gepotidacin could offer a novel oral treatment option for patients who cannot take other treatments due to allergies or intolerance.
February 26, 2024
11 Articles